Advocacy intelligence hub — real-time data for patient organizations
Shanghai Eye Disease Prevention and Treatment Center — NA
Quan Dong Nguyen — PHASE2
Oslo University Hospital — PHASE4
Affiliated Hospital of Nantong University — PHASE3
Massachusetts Eye and Ear Infirmary — PHASE1, PHASE2
Vance Thompson Vision - MT — PHASE4
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Eylea
(aflibercept)Orphan drugstandardRegeneron Pharmaceuticals, Inc.
Vascular Endothelial Growth Factor Inhibitor [EPC]
12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic...
Krintafel
(tafenoquine)Orphan drugstandardGlaxoSmithKline Intellectual Property Development Ltd. England
12.1 Mechanism of Action Tafenoquine is an 8-aminoquinoline antimalarial drug [see Microbiology ( 12.4 )].
Paolo Rama, MD
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele
Christine FARDEAU, MD
Assistance Publique Hopitaux de Paris
Gilda Cennamo
Università Federico II
Quan D Nguyen, MD, MSc
Johns Hopkins University
Simone Donati, MD
Università dell'Insubria
Hamid Ahmadieh, MD
Ophthalmic Research Center of Shaheed Beheshti Medical University